(THC) Tenet Healthcare - Ratings and Ratios
Hospitals, Ambulatory Care, Surgical Centers, Urgent Care, Imaging Centers
THC EPS (Earnings per Share)
THC Revenue
Description: THC Tenet Healthcare
Tenet Healthcare Corporation is a diversified healthcare services company operating in the United States, with a presence in hospital operations, ambulatory care, and various healthcare services. The companys broad range of services includes acute care, specialized treatment services, outpatient services, and tertiary care services, catering to diverse patient needs.
From a business perspective, Tenet Healthcares operational segments can be analyzed through key performance indicators (KPIs) such as revenue growth, operating margin, and patient volume. The companys ability to expand its services and improve operational efficiency can be measured by tracking metrics like same-store sales growth and adjusted EBITDA margin. With a strong presence in the healthcare industry, Tenet Healthcares competitive positioning can be assessed by analyzing its market share, hospital admissions, and outpatient visits.
To evaluate the companys financial health, we can examine KPIs such as debt-to-equity ratio, interest coverage ratio, and return on invested capital (ROIC). Tenet Healthcares ability to generate cash flows and invest in growth opportunities can be gauged by analyzing its free cash flow conversion and capital expenditure as a percentage of revenue. With a market capitalization of $15.92 billion, the companys valuation can be assessed using metrics like enterprise value-to-EBITDA (EV/EBITDA) and price-to-book (P/B) ratio.
Tenet Healthcares commitment to quality care and patient outcomes can be evaluated by tracking quality metrics such as patient satisfaction scores, readmission rates, and hospital-acquired condition rates. The companys strategic initiatives, such as investments in digital health and telemedicine, can be assessed by analyzing their impact on patient engagement, cost savings, and revenue growth.
THC Stock Overview
| Market Cap in USD | 17,009m |
| Sub-Industry | Health Care Facilities |
| IPO / Inception | 1982-01-04 |
THC Stock Ratings
| Growth Rating | 74.0% |
| Fundamental | 72.3% |
| Dividend Rating | 6.27% |
| Return 12m vs S&P 500 | -1.38% |
| Analyst Rating | 4.32 of 5 |
THC Dividends
Currently no dividends paidTHC Growth Ratios
| Growth Correlation 3m | 57.3% |
| Growth Correlation 12m | 42.6% |
| Growth Correlation 5y | 78.5% |
| CAGR 5y | 48.32% |
| CAGR/Max DD 3y | 1.31 |
| CAGR/Mean DD 3y | 7.53 |
| Sharpe Ratio 12m | 0.86 |
| Alpha | 0.01 |
| Beta | 0.886 |
| Volatility | 37.79% |
| Current Volume | 845.4k |
| Average Volume 20d | 978.4k |
| Stop Loss | 177.9 (-3%) |
| Signal | 0.32 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (1.48b TTM) > 0 and > 6% of Revenue (6% = 1.24b TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -0.98pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 14.63% (prev 11.77%; Δ 2.86pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 2.46b > Net Income 1.48b (YES >=105%, WARN >=100%) |
| Net Debt (10.55b) to EBITDA (4.62b) ratio: 2.29 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.71 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (91.8m) change vs 12m ago -6.76% (target <= -2.0% for YES) |
| Gross Margin 51.24% (prev 30.30%; Δ 20.94pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 71.38% (prev 71.47%; Δ -0.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.66 (EBITDA TTM 4.62b / Interest Expense TTM 815.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.18
| (A) 0.11 = (Total Current Assets 7.30b - Total Current Liabilities 4.27b) / Total Assets 28.70b |
| (B) 0.13 = Retained Earnings (Balance) 3.70b / Total Assets 28.70b |
| (C) 0.13 = EBIT TTM 3.80b / Avg Total Assets 28.98b |
| (D) 0.17 = Book Value of Equity 3.53b / Total Liabilities 20.40b |
| Total Rating: 2.18 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 72.34
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 5.67% = 2.84 |
| 3. FCF Margin 7.56% = 1.89 |
| 4. Debt/Equity 3.51 = -1.49 |
| 5. Debt/Ebitda 2.85 = -1.56 |
| 6. ROIC - WACC (= 11.47)% = 12.50 |
| 7. RoE 37.25% = 2.50 |
| 8. Rev. Trend -3.56% = -0.27 |
| 9. EPS Trend 88.50% = 4.42 |
What is the price of THC shares?
Over the past week, the price has changed by -4.33%, over one month by +7.09%, over three months by +9.56% and over the past year by +16.89%.
Is Tenet Healthcare a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of THC is around 218.87 USD . This means that THC is currently undervalued and has a potential upside of +19.29% (Margin of Safety).
Is THC a buy, sell or hold?
- Strong Buy: 12
- Buy: 5
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the THC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 197.5 | 7.7% |
| Analysts Target Price | 197.5 | 7.7% |
| ValueRay Target Price | 238 | 29.7% |
Last update: 2025-09-05 05:04
THC Fundamental Data Overview
CCE Cash And Equivalents = 2.62b USD (last quarter)
P/E Trailing = 12.1006
P/E Forward = 12.0773
P/S = 0.8224
P/B = 4.4048
P/EG = 0.8537
Beta = 1.557
Revenue TTM = 20.69b USD
EBIT TTM = 3.80b USD
EBITDA TTM = 4.62b USD
Long Term Debt = 13.09b USD (from longTermDebt, last quarter)
Short Term Debt = 84.0m USD (from shortTermDebt, last quarter)
Debt = 13.18b USD (Calculated: Short Term 84.0m + Long Term 13.09b)
Net Debt = 10.55b USD (from netDebt column, last quarter)
Enterprise Value = 27.56b USD (17.01b + Debt 13.18b - CCE 2.62b)
Interest Coverage Ratio = 4.66 (Ebit TTM 3.80b / Interest Expense TTM 815.0m)
FCF Yield = 5.67% (FCF TTM 1.56b / Enterprise Value 27.56b)
FCF Margin = 7.56% (FCF TTM 1.56b / Revenue TTM 20.69b)
Net Margin = 7.17% (Net Income TTM 1.48b / Revenue TTM 20.69b)
Gross Margin = 51.24% ((Revenue TTM 20.69b - Cost of Revenue TTM 10.09b) / Revenue TTM)
Tobins Q-Ratio = 7.80 (Enterprise Value 27.56b / Book Value Of Equity 3.53b)
Interest Expense / Debt = 1.56% (Interest Expense 206.0m / Debt 13.18b)
Taxrate = 22.56% (1.18b / 5.25b)
NOPAT = 2.94b (EBIT 3.80b * (1 - 22.56%))
Current Ratio = 1.71 (Total Current Assets 7.30b / Total Current Liabilities 4.27b)
Debt / Equity = 3.51 (Debt 13.18b / last Quarter total Stockholder Equity 3.75b)
Debt / EBITDA = 2.85 (Net Debt 10.55b / EBITDA 4.62b)
Debt / FCF = 8.43 (Debt 13.18b / FCF TTM 1.56b)
Total Stockholder Equity = 3.98b (last 4 quarters mean)
RoA = 5.17% (Net Income 1.48b, Total Assets 28.70b )
RoE = 37.25% (Net Income TTM 1.48b / Total Stockholder Equity 3.98b)
RoCE = 22.25% (Ebit 3.80b / (Equity 3.98b + L.T.Debt 13.09b))
RoIC = 17.22% (NOPAT 2.94b / Invested Capital 17.08b)
WACC = 5.76% (E(17.01b)/V(30.18b) * Re(9.28%)) + (D(13.18b)/V(30.18b) * Rd(1.56%) * (1-Tc(0.23)))
Shares Correlation 3-Years: -100.00 | Cagr: -1.62%
Discount Rate = 9.28% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 77.53% ; FCFE base≈1.69b ; Y1≈2.09b ; Y5≈3.56b
Fair Price DCF = 546.6 (DCF Value 48.29b / Shares Outstanding 88.4m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 88.50 | EPS CAGR: 45.26% | SUE: 2.47 | # QB: 4
Revenue Correlation: -3.56 | Revenue CAGR: 2.29% | SUE: N/A | # QB: None
Additional Sources for THC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle